Home › Companies › Protagonist Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 17, 2026: 5 items on Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026: 3 approved · 2 passed (calculated).
Notable dissent: 1 director (13.9% against); 1 equity or compensation plan (15.6% against); 1 other board item (19.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Protagonist Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Protagonist Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dinesh V. Patel, Ph.D. | 48,714,702 | -- | -- | 7,875,311 | 2,819,234 | 86% | Passed (calculated) | — |
| Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D. | 45,371,193 | -- | -- | 11,218,820 | 2,819,234 | 80% | Passed (calculated) | — |
| 2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 53,412,559 | 3,164,702 | 12,752 | -- | 2,819,234 | 94% | Approved | — |
| 3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 | 59,371,487 | 28,221 | 9,539 | -- | -- | 99.9% | Approved | — |
| 4. To approve the adoption of the Company's 2026 Equity Incentive Plan | 47,745,562 | 8,826,703 | 17,748 | -- | 2,819,234 | 84% | Approved | — |
Source: Protagonist Therapeutics, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
362 asset managers disclosed a vote on at least one Protagonist Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dinesh V. Patel, Ph.D.
Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Dinesh V. Patel, Ph.D.”): 48,714,702 for, 7,875,311 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 25,050,958 for, 1,620,821 withheld, 357,599 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,775 | 0 | 56 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 773,456 | 0 | 0 | 890 | For |
| Prudential/PGIM | 484,616 | 0 | 0 | 4,528 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 412,809 | Withhold |
| Jackson National | 188,307 | 0 | 198,749 | 0 | Mixed |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 235,216 | 0 | 0 | 6,209 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 172,647 | 0 | 0 | 0 | For |
| Victory Capital | 544 | 0 | 0 | 161,490 | Withhold |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 138,752 | Withhold |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| Brighthouse | 107,116 | 0 | 0 | 18,373 | Mixed |
| John Hancock | 51,440 | 0 | 73,361 | 0 | Mixed |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 108,768 | Withhold |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.
Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.”): 45,371,193 for, 11,218,820 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 22,858,860 for, 3,225,193 withheld, 945,325 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,754 | 0 | 77 | 0 | For |
| BlackRock | 5,438,131 | 0 | 553,803 | 0 | Mixed |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,349,085 | Withhold |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 773,456 | 0 | 0 | 890 | For |
| Prudential/PGIM | 484,616 | 0 | 0 | 4,528 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 412,809 | Withhold |
| Jackson National | 186,952 | 0 | 200,104 | 0 | Mixed |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 235,216 | 0 | 0 | 6,209 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 172,647 | 0 | 0 | 0 | For |
| Victory Capital | 544 | 0 | 0 | 161,490 | Withhold |
| Equitable | 82,788 | 0 | 0 | 63,241 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 138,752 | Withhold |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| Brighthouse | 94,311 | 0 | 0 | 31,178 | Mixed |
| John Hancock | 27,444 | 0 | 97,357 | 0 | Mixed |
| TIAA | 0 | 0 | 0 | 118,095 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 108,768 | Withhold |
Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
84% Approved · of votes cast
Description as filed by funds: TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.
Protagonist Therapeutics, Inc.’s own tally for this item (“4. To approve the adoption of the Company's 2026 Equity Incentive Plan”): 47,745,562 for, 8,826,703 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,179,222 | 17,609 | 0 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 772,559 | 1,787 | 0 | 0 | For |
| Prudential/PGIM | 481,376 | 7,768 | 0 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 0 | 412,809 | 0 | 0 | Against |
| Jackson National | 188,307 | 198,749 | 0 | 0 | Mixed |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 0 | 304,405 | 0 | 0 | Against |
| Legg Mason | 235,216 | 6,209 | 0 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 6,532 | 172,647 | 0 | 0 | Against |
| Victory Capital | 544 | 161,490 | 0 | 0 | Against |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 138,752 | 0 | 0 | Against |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| John Hancock | 51,440 | 73,361 | 0 | 0 | Mixed |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 108,768 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 94,595 | 0 | 0 | 0 | For |
Fund voting reports, all 105 managers: 24,438,127 for, 2,451,413 against, 14,349 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Duquesne Family Office LLC | 159,700 | 0 | 0 | 0 | For |
| NEXTBio Capital Management LP | 152,866 | 0 | 0 | 0 | For |
| Vident Advisory, LLC | 4,698 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 4,292 | 0 | 0 | 0 | For |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 504 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 140 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 322,200 for.
Combines 7 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 94.7% for (June 20, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
Protagonist Therapeutics, Inc.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 53,412,559 for, 3,164,702 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,822 | 9 | 0 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 457,668 | 1,113,019 | 0 | 0 | Mixed |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 774,025 | 321 | 0 | 0 | For |
| Prudential/PGIM | 489,144 | 0 | 0 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 412,809 | 0 | 0 | 0 | For |
| Jackson National | 200,104 | 186,952 | 0 | 0 | Mixed |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 241,425 | 0 | 0 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 179,179 | 0 | 0 | 0 | For |
| Victory Capital | 162,034 | 0 | 0 | 0 | For |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 138,752 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| Brighthouse | 31,178 | 94,311 | 0 | 0 | Mixed |
| John Hancock | 124,801 | 0 | 0 | 0 | For |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,768 | 0 | 0 | 0 | For |
Fund voting reports, all 107 managers: 25,550,429 for, 1,483,388 against, 9,310 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 5,059,053 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 4,779,080 | 0 | 0 | 0 | For |
| Janus Henderson | 3,439,829 | 0 | 0 | 0 | For |
| Wellington | 2,703,511 | 0 | 0 | 0 | For |
| BlackRock | 1,834,489 | 31,019 | 0 | 0 | For |
| State Street | 1,863,089 | 321 | 0 | 0 | For |
| T. Rowe Price | 1,749,645 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,679,699 | 0 | 0 | 0 | For |
| Invesco | 30,938 | 1,530,435 | 0 | 0 | Against |
| Woodline Partners LP | 1,219,306 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 908,483 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 835,481 | 0 | 0 | 0 | For |
| Fidelity | 666,340 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 623,901 | 0 | 0 | 0 | For |
| Charles Schwab | 553,717 | 0 | 0 | 0 | For |
| Northern Trust | 522,701 | 4,088 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 516,333 | 0 | 0 | 0 | For |
| Vanguard | 503,454 | 0 | 0 | 0 | For |
| American Century | 461,158 | 0 | 0 | 0 | For |
| Voya | 418,589 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 377,236 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 369,014 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 361,142 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 348,171 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 334,341 | 164 | 0 | 0 | For |
Institutional-manager reports, all 284 managers: 38,002,679 for, 2,644,148 against, 139 abstained, 3,689 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 20, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Protagonist Therapeutics, Inc.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 59,371,487 for, 28,221 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 107 asset managers below reported 27,009,492 for, 24,325 against, 9,310 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,196,831 | 0 | 0 | 0 | For |
| BlackRock | 5,991,934 | 0 | 0 | 0 | For |
| Fidelity | 2,154,091 | 0 | 0 | 0 | For |
| Invesco | 1,570,687 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,349,085 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 978,011 | 0 | 0 | 0 | For |
| State Street | 774,346 | 0 | 0 | 0 | For |
| Prudential/PGIM | 489,144 | 0 | 0 | 0 | For |
| Charles Schwab | 482,250 | 0 | 0 | 0 | For |
| American Century | 412,809 | 0 | 0 | 0 | For |
| Jackson National | 387,056 | 0 | 0 | 0 | For |
| Lord Abbett | 343,358 | 0 | 0 | 0 | For |
| Voya | 304,405 | 0 | 0 | 0 | For |
| Legg Mason | 241,425 | 0 | 0 | 0 | For |
| Hartford | 226,240 | 0 | 0 | 0 | For |
| Putnam | 179,179 | 0 | 0 | 0 | For |
| Victory Capital | 162,034 | 0 | 0 | 0 | For |
| Equitable | 146,029 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 138,752 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 133,815 | 0 | 0 | 0 | For |
| JPMorgan | 133,312 | 0 | 0 | 0 | For |
| Brighthouse | 125,489 | 0 | 0 | 0 | For |
| John Hancock | 124,801 | 0 | 0 | 0 | For |
| TIAA | 118,095 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 108,768 | 0 | 0 | 0 | For |
Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,227,057 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.76% |
| 2 | BlackRock | 9.33% |
| 3 | Fidelity | 3.35% |
| 4 | Invesco | 2.45% |
| 5 | T. Rowe Price | 2.10% |
| 6 | JANUS INVESTMENT FUND | 1.52% |
| 7 | State Street | 1.21% |
| 8 | Prudential/PGIM | 0.76% |
| 9 | Charles Schwab | 0.75% |
| 10 | American Century | 0.64% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 7.88% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.44% |
| 3 | Janus Henderson | 5.36% |
| 4 | Wellington | 4.21% |
| 5 | BlackRock | 2.90% |
| 6 | State Street | 2.90% |
| 7 | T. Rowe Price | 2.72% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.62% |
| 9 | Invesco | 2.43% |
| 10 | Woodline Partners LP | 1.90% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 9,779,369 | 15.23% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with BlackRock, Inc. | 8,575,669 | 13.35% | Proxy statement (DEF 14A), table as of March 13, 2026 |
| Farallon Capital Management, L.L.C. | 6,433,119 | 10.02% | Schedule 13G, filed August 13, 2026 |
| Entities affiliated with Farallon Partners, L.L.C. | 6,401,006 | 9.97% | Proxy statement (DEF 14A), table as of March 13, 2026 |
| Entities affiliated with The Vanguard Group | 5,413,690 | 8.43% | Proxy statement (DEF 14A), table as of March 13, 2026 |
| Vanguard Group | 5,413,690 | 8.43% | Form 13F, quarter ended March 31, 2026 |
| Entities affiliated with RTW Investments, L.P. | 5,059,053 | 7.88% | Proxy statement (DEF 14A), table as of March 13, 2026 |
| RTW Investments, LP | 5,059,053 | 7.88% | Schedule 13G, filed February 17, 2026 |
| Wellington Management | 3,599,644 | 5.60% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Portfolio Management | 3,533,015 | 5.50% | Schedule 13G, filed April 29, 2026 |
Percentages above are of 64,227,057 shares outstanding, as reported by Protagonist Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Protagonist Therapeutics, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 362 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,507 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Protagonist Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Protagonist Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Protagonist Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Protagonist Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Protagonist Therapeutics (PTGX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/protagonist-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.